ReviewInternational journal of nephrology and renovascular disease2018

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.

Laia Sans-Atxer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.